← Leaderboards
Wolfgang Weber
Sloan-Kettering Inst Can Research
$588,124
Attributed
$1,980,446
Total exposure
4
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $640.6K · FY2015–19$1M$750K$500K$250K$0
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$1,980,446 · 4
By mechanism
R01$1,793,621 · 3
R21$186,825 · 1
Top collaborators
- Jason S Lewis3 shared
- Michael I D'Angelica2 shared
- Neeta Pandit Taskar2 shared
- Thomas Reiner2 shared
- Balu Easwaramoorthy1 shared
- Joseph Reginald Osborne1 shared
- John Thomas Poirier1 shared
- Charles M Rudin1 shared
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- John Thomas Poirier$4,490,380
- Thomas Reiner$4,804,085
- Jason S Lewis$26,024,327
- Nagavarakishore Pillarsetty$8,324,037
- Balu Easwaramoorthy$752,454
Others in their field
Top investigators on “Uptake”
- Deborah J Donnell · Fred Hutchinson Cancer Center$72,734,465
- Diane V Havlir · University Of California, San Francisco$59,450,416
- Keith A. Johnson · Banner Health$53,901,946
- Adam L Boxer · Mayo Clinic Rochester$45,623,508
- Jose A Luchsinger · Columbia University Health Sciences$26,528,293
- Daniel J Feaster · University Of Miami School Of Medicine$25,552,939
Research focus
UptakeDoseMalignant NeoplasmsTumorLabelImageMemorial Sloan-Kettering Cancer CenterBaseClinical TrialsSerumRadiation TherapyPre-ClinicalRadioisotopesImaging AgentTumor TissueClinicNormal Tissue MorphologyMalignant - DescriptorMedicalNuclearIsotopesCancer ImagingKidneyIn Vitro
Grant awards (6)
Histopathologic validation of 89Zr-DFO-HuMab-5B1 PET/CT imaging in CA 19-9 positive pancreatic cancer$398,509
R01 · FY2019 · CA
Histopathologic validation of 89Zr-DFO-HuMab-5B1 PET/CT imaging in CA 19-9 positive pancreatic cancer$392,764
R01 · FY2018 · CA
Immuno-PET imaging of high-grade neuroendocrine lung tumors using 89Zr-rovalpituzumab, a DLL3-targeting monoclonal antibody$446,668
R01 · FY2017 · CA
A new technique to make 68Ga-labeled pharmaceuticals widely available for clinical use$555,680
R01 · FY2016 · CA · contact PI
Development of Nuclear Auger Emitters for Targeted Radiotherapy$84,921
R21 · FY2016 · CA
Development of Nuclear Auger Emitters for Targeted Radiotherapy$101,904
R21 · FY2015 · CA